<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213732</url>
  </required_header>
  <id_info>
    <org_study_id>PH-L19TNFαILP-01-08</org_study_id>
    <nct_id>NCT01213732</nct_id>
  </id_info>
  <brief_title>Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma</brief_title>
  <official_title>Phase 1 Dose-finding Study of Tumor-targeting Human Monoclonal Antibody-cytokine Fusion Protein L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion in Patients With In-transit Stage III/IV Melanoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philogen S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InnoPharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eudax S.r.l.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Philogen S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the&#xD;
      standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV&#xD;
      limb melanoma.&#xD;
&#xD;
      The recombinant human fusion protein L19TNFα was created with the intention to target TNFα&#xD;
      directly to tumor tissues with the result in high and sustained intralesional bioactive TNFα&#xD;
      concentrations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>6 weeks</time_frame>
    <description>The safety and tolerability profile of L19TNFα/melphalan combination treatment in the ILP setting will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose (RD)</measure>
    <time_frame>29 days</time_frame>
    <description>The recommended dose (RD) of L19TNFα when given in combination with melphalan in the ILP setting for subjects with limb stage III/IV melanoma will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>10 weeks</time_frame>
    <description>Objective response rate of L19TNFα plus melphalan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>4- 6 weeks</time_frame>
    <description>Antitumor activity of L19TNFα plus melphalan (resection of residual tumor after 4- 6 weeks and histopathological response rate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic</measure>
    <time_frame>10 days</time_frame>
    <description>Pharmacokinetic profile of L19TNFα when given with melphalan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human anti-fusion protein antibody</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessment of possible induction of human anti-fusion protein antibody [HAFA] formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-hydroxyindoleacetic acid</measure>
    <time_frame>10 days</time_frame>
    <description>Assessment of plasma profile of 5-hydroxyindoleacetic acid (5-HIAA), a surrogate marker of vascular damage and tumor response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Patients With Intransit Stage III/IV Melanoma of Lower Extremity Distal to the Apex of the Femoral Triangle.</condition>
  <arm_group>
    <arm_group_label>L19TNFα plus melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be sequentially assigned to one of 2 dose levels of L19TNFα: 325 µg or 650 µg. All subjects will receive a single dose of L19TNFα and Melfalan (10mg/ L Limb volume).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isolated inferior limb perfusion</intervention_name>
    <description>Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).</description>
    <arm_group_label>L19TNFα plus melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged &gt;18 years.&#xD;
&#xD;
          2. Histologically or cytologically confirmed intransit stage III/IV melanoma of lower&#xD;
             extremity distal to the apex of the femoral triangle&#xD;
&#xD;
          3. ECOG performance status ≤ 2.&#xD;
&#xD;
          4. Subjects must have at least one unidimensional clinically measurable lesion as defined&#xD;
             by RECIST criteria (see Section 8). This lesion must not have been irradiated within&#xD;
             four weeks during previous treatments.&#xD;
&#xD;
          5. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and&#xD;
             haemoglobin (Hb) ≥ 9.5 g/dl.&#xD;
&#xD;
          6. All acute adverse effects (excluding alopecia) of any prior therapy (including&#xD;
             surgery, radiation therapy, chemotherapy) must have been resolved to ≤ Grade 1, except&#xD;
             elevated liver transaminases judged to be associated with tumor infiltration (see&#xD;
             below) (graded according to National Cancer Institute [NCI] Common Terminology&#xD;
             Criteria for Adverse Events, version 3.0 [CTCAE, v.3.0].&#xD;
&#xD;
          7. Alkaline phosphatase (AP), alanine aminotransferase (ALT) and/or aspartate&#xD;
             aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN), and total bilirubin ≤ 2.0&#xD;
             mg/dL unless liver involvement by the tumor, in which case the transaminase levels up&#xD;
             to 5 x ULN are allowed.&#xD;
&#xD;
          8. Creatinine ≤ 1.5 ULN or 24 h creatinine clearance ≥ 60 mL/min.&#xD;
&#xD;
          9. Testing negative for acute or chronic infection with hepatitis B or C virus, or human&#xD;
             immunodeficiency virus 1 or 2.&#xD;
&#xD;
         10. Negative pregnancy test for females of childbearing potential at the screening visit.&#xD;
&#xD;
         11. Commitment from subject to practice medically appropriate/acceptable method of birth&#xD;
             control (e.g., hormonal, condoms or other adequate barrier controls, intrauterine&#xD;
             contraceptive device, or sterilization) beginning at the screening visit and&#xD;
             continuing until 3 months following the treatment with study drug&#xD;
&#xD;
         12. Able to provide written Informed Consent&#xD;
&#xD;
         13. Willingness and ability to comply with the scheduled visits, treatment plan,&#xD;
             laboratory tests and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Breastfeeding women&#xD;
&#xD;
          2. Presence of active infections (e.g. requiring antimicrobial therapy) or other severe&#xD;
             concurrent disease, which, in the opinion of the Investigator, would place the subject&#xD;
             at undue risk or interfere with the study.&#xD;
&#xD;
          3. Active autoimmune disease.&#xD;
&#xD;
          4. Cardiac disease as manifested by any of the following:&#xD;
&#xD;
               -  &gt; Grade II heart failure, graded per New York Heart Association (NYHA) criteria.&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Acute or subacute coronary syndromes, including myocardial infarction, occurring&#xD;
                  with 1 year prior to study treatment&#xD;
&#xD;
               -  Arrhythmia needing continuous treatment&#xD;
&#xD;
               -  Ejection fraction less than the institutional lower limit of normal as assessed&#xD;
                  by multigated radionuclide angiography (MUGA) scan or echocardiogram&#xD;
&#xD;
          5. Uncontrolled hypertension.&#xD;
&#xD;
          6. History of claudication or Ischemic peripheral vascular disease (Grade IIb-IV).&#xD;
&#xD;
          7. Chronic obstructive pulmonary disease or other chronic pulmonary disease with PFTs&#xD;
             less than 50% predicted for age.&#xD;
&#xD;
          8. Symptomatic cerebrovascular disease.&#xD;
&#xD;
          9. Active peptic ulcer disease.&#xD;
&#xD;
         10. Concurrent infection of HIV.&#xD;
&#xD;
         11. Severe diabetic retinopathy.&#xD;
&#xD;
         12. Major surgery or trauma within 4 weeks prior to start of study treatment.&#xD;
&#xD;
         13. Hypersensitivity to melphalan or TNFα or other intravenously administered human&#xD;
             proteins/peptides/antibodies.&#xD;
&#xD;
         14. Chemotherapy, radiation therapy or therapy with an investigational agent within 4&#xD;
             weeks prior to start of study treatment.&#xD;
&#xD;
         15. Any regional therapy to the affected extremity within 2 months prior to start of study&#xD;
             treatment.&#xD;
&#xD;
         16. Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6&#xD;
             weeks before administration of study treatment.&#xD;
&#xD;
         17. Growth factors or immunomodulatory agents within 7 days prior to the administration of&#xD;
             study treatment.&#xD;
&#xD;
         18. Subject requires or is taking corticosteroids or other immunosuppressant drugs on a&#xD;
             long-term basis. Limited use of corticosteroids to treat or prevent acute&#xD;
             hypersensitivity reactions is not considered an exclusion criterion.&#xD;
&#xD;
         19. Participation in another interventional clinical trial during participation in this&#xD;
             trial.&#xD;
&#xD;
         20. Any conditions that in the opinion of the Investigator could hamper compliance with&#xD;
             the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco De Cian, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>September 22, 2011</last_update_submitted>
  <last_update_submitted_qc>September 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L19, antibody, monoclonal, tumor targeting, TNFa, ILP, melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

